Biogen (BIIB) Morgan Stanley raised the target to $373 from $361
Analyst Ratings Coverage Morgan Stanley & Co. (Rank#1) has recently issued a research report, maintaining its “Overweight” rating on Biogen’s stock, signaling…
Browse research
Analyst Ratings Coverage Morgan Stanley & Co. (Rank#1) has recently issued a research report, maintaining its “Overweight” rating on Biogen’s stock, signaling…
AstraZeneca’s Strategic Move: A $2 Billion Bet on Eccogene’s Anti-Obesity Drug On Thursday, pharmaceutical giant AstraZeneca made a significant strategic move by…
Canopy Growth’s Resilience Shows as Second-Quarter Core Loss Narrows Leading pot producer Canopy Growth has reported a smaller adjusted core loss for…
Suncor Energy Q3 Suncor Energy, one of Canada’s leading integrated energy companies, reported a third-quarter profit that exceeded market expectations. The impressive…
AMC Entertainment (AMC:NYE), a major movie theater chain, has reported a strong 3rd quarter of 2023, surpassing analyst projections and reaching record…